Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.65 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.33 |
| ▸ | MC3R | P41968 | 2/20 | 0.33 |
| ▸ | MC1R | Q01726 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042253 | 1.00 | AR (0.65) | ARCTSBMC4RMC3RMC1R | |
| SCHEMBL4047983 | 0.92 | AR (0.68) | ARCTSBALDH1A1 | |
| SCHEMBL6379526 | 0.92 | AR (0.68) | ARCTSBALDH1A1 | |
| SCHEMBL5092450 | 0.89 | AR (0.65) | ARCTSBKMT2AALDH1A1MEN1 | |
| SCHEMBL4037420 | 0.89 | AR (0.65) | ARCTSBKMT2AALDH1A1MEN1 | |
| SCHEMBL6375514 | 0.89 | AR (0.65) | ARCTSBKMT2AALDH1A1MEN1 | |
| SCHEMBL5099264 | 0.89 | AR (0.65) | ARCTSBKMT2AALDH1A1MEN1 | |
| SCHEMBL4039836 | 0.89 | AR (0.65) | ARCTSBKMT2AALDH1A1MEN1 | |
| SCHEMBL5093823 | 0.87 | AR (0.68) | AR | |
| SCHEMBL4038981 | 0.86 | AR (0.63) | ARCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | NR2C2, NR0B2, NR0B1 | AR 32/4885CTSB 4693/4885MC4R 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.